These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2295005)

  • 1. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components.
    Saarinen UM; Kekomäki R; Siimes MA; Myllylä G
    Blood; 1990 Jan; 75(2):512-7. PubMed ID: 2295005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer.
    Saarinen UM; Koskimies S; Myllylä G
    Vox Sang; 1993; 65(4):286-92. PubMed ID: 8310680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
    Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G
    Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocyte-depleted blood components prevent platelet refractoriness in patients with acute myeloid leukemia.
    Oksanen K
    Eur J Haematol; 1994 Aug; 53(2):100-7. PubMed ID: 8088380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A; Pavenski K
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
    Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
    Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
    Sniecinski I; O'Donnell MR; Nowicki B; Hill LR
    Blood; 1988 May; 71(5):1402-7. PubMed ID: 3282572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
    Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
    Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
    Trial to Reduce Alloimmunization to Platelets Study Group
    N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
    van Marwijk Kooy M; van Prooijen HC; Moes M; Bosma-Stants I; Akkerman JW
    Blood; 1991 Jan; 77(1):201-5. PubMed ID: 1984797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical aspects of platelet transfusions.
    Murphy MF; Waters AH
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet transfusions: the problem of refractoriness.
    Murphy MF; Waters AH
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Refractory effect and alloimmunization after transfusion of thrombocytes].
    Volkova RI; Agranenko VA
    Gematol Transfuziol; 1992 Feb; 37(2):16-21. PubMed ID: 1426903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
    Eernisse JG; Brand A
    Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions.
    Brand A; Claas FH; Voogt PJ; Wasser MN; Eernisse JG
    Vox Sang; 1988; 54(3):160-6. PubMed ID: 3369136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
    Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
    Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
    Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
    Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and circumvention of refractoriness to platelet transfusions: interface between preparative and therapeutic apheresis.
    Beris P; Dornier C
    Curr Stud Hematol Blood Transfus; 1990; (57):267-76. PubMed ID: 2272206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.